JP Morgan Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains a Neutral rating on Teva Pharmaceutical Industries (NYSE:TEVA) but raises the price target from $16 to $18.
October 21, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has maintained a Neutral rating on Teva Pharmaceutical Industries but increased the price target from $16 to $18, indicating a slightly more positive outlook.
The increase in the price target from $16 to $18 suggests a more optimistic view on Teva's future performance, which could lead to a positive short-term impact on the stock price. However, the Neutral rating indicates that the analyst does not see a strong buy opportunity, which tempers the potential impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100